Kraj: Kanada
Język: angielski
Źródło: Health Canada
LEVETIRACETAM
APOTEX INC
N03AX14
LEVETIRACETAM
500MG
TABLET
LEVETIRACETAM 500MG
ORAL
100
Prescription
MISCELLANEOUS ANTICONVULSANTS
Active ingredient group (AIG) number: 0148843002; AHFS:
APPROVED
2006-09-21
_APO-LEVETIRACETAM (levetiracetam tablets) _ _ _ _Page 1 of 42_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR APO-LEVETIRACETAM Levetiracetam Tablets Tablets, 250 mg, 500 mg and 750 mg, Oral USP Antiepileptic ATC Code: N03AX14 APOTEX INC. 150 Signet Drive Toronto, Ontario M9L 1T9 Date of Initial Authorization: SEP 21, 2006 Date of Revision: MAY 1, 2023 Submission Control Number: 270431 _APO-LEVETIRACETAM (levetiracetam tablets) _ _ _ _Page 2 of 42_ RECENT MAJOR LABEL CHANGES 7 WARNINGS AND PRECAUTIONS, Neurologic 05/2023 7 WARNINGS AND PRECAUTIONS, Cardiovascular 05/2023 7 WARNINGS AND PRECAUTIONS, Psychiatric 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS .................................................................................................................. 4 1.1 Pediatrics .................................................................................................................... 4 1.2 Geriatrics .................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................... 4 4 DOSAGE AND ADMINISTRATION .................................................................................... 4 4.1 Dosing Considerations ................................................................................................ 4 4.2 Recommended Dose and Dosage Adjustment ........................................................... 4 4.4 Administration ....................................... Przeczytaj cały dokument